HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BioNTech with a maintained price target of $113.
August 19, 2024 | 12:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BioNTech, maintaining a price target of $113, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $113 price target by HC Wainwright & Co. suggests a positive outlook for BioNTech, likely boosting investor confidence and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100